Brought to you by

Janssen Biotech gets rights to autoimmune/inflammation compounds from Phenex
04 Aug 2017
Executive Summary
Johnson & Johnson’s Janssen Biotech Inc. has licensed exclusive rights to Phenex Pharmaceuticals AG’s (small-molecule therapeutics for liver disease and autoimmune/inflammatory disorders) compounds targeting the nuclear hormone receptor RORyt to treat chronic autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com